NewEdge Wealth LLC Buys New Position in Medpace Holdings, Inc. $MEDP

NewEdge Wealth LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, Holdings Channel.com reports. The fund purchased 51,943 shares of the company’s stock, valued at approximately $27,508,000.

Several other large investors have also added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Medpace during the 2nd quarter valued at $1,323,047,000. AQR Capital Management LLC lifted its position in shares of Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after purchasing an additional 324,293 shares during the period. Wasatch Advisors LP lifted its position in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares during the period. Geode Capital Management LLC lifted its position in shares of Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

MEDP stock opened at $608.27 on Thursday. The firm has a 50 day moving average price of $544.34 and a 200-day moving average price of $491.59. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The firm has a market capitalization of $16.98 billion, a price-to-earnings ratio of 35.65, a PEG ratio of 2.63 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the prior year, the business posted $3.10 EPS. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Cornelius P. Mccarthy III sold 1,140 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total value of $690,121.80. Following the sale, the director directly owned 12,275 shares of the company’s stock, valued at approximately $7,430,916.75. This represents a 8.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the transaction, the vice president owned 62,984 shares of the company’s stock, valued at $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 67,195 shares of company stock valued at $37,989,998. 20.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and raised their price objective for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Leerink Partners set a $620.00 price objective on Medpace in a research report on Thursday, July 23rd. Truist Financial upped their target price on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Finally, Barclays set a $600.00 target price on Medpace in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.